Description

Eterna Peptides presents premium-grade Retatrutide (GLP-3 Architecture) lyophilized powder, an elite synthetically structured peptide analogue representing the absolute cutting edge of metabolic research. Functioning as a revolutionary triple mono-agonist, Retatrutide binds concurrently to the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. Its Backbone structure is uniquely modified with a custom C20 fatty diacid moiety that optimizes stable albumin binding to drastically extend its metabolic research half-life. Available in standalone single vials across 5mg, 10mg, 30mg, and 60mg mass configurations, this premium compound serves as the ultimate investigative tool for tracking triple-incretin receptor activation, high-velocity cellular lipid mobilization, and intensive energy expenditure adaptation.

### Available Research Configurations
* **Retatrutide 5mg Vial:** Standardized for early-stage baseline metabolic exposure screens and short-duration cell assay tracking.
* **Retatrutide 10mg Vial:** Calibrated for mid-tier longitudinal tracking protocols and standard weight management simulation models.
* **Retatrutide 30mg Vial:** High-capacity presentation engineered for advanced multi-subject protocols and continuous cellular saturation profiles.
* **Retatrutide 60mg Vial:** Ultra-concentrated mass configuration optimized for intensive dose-response screens and extended experimental timelines.

### Mechanism of Action
Retatrutide operates via a unique triple-agonist architecture that yields unparalleled metabolic signaling compared to single or dual incretin mono-therapies:
* **GIP Receptor Path Bias:** Retatrutide acts as a potent full agonist at the GIP receptor network, driving efficient intracellular cyclic AMP ($cAMP$) accumulation to study optimal pancreatic beta-cell insulin secretion dynamics and white adipose tissue repartitioning.
* **GLP-1 Receptor Satiety Alignment:** It acts as a biased agonist at the GLP-1 receptor path, crossing blood-brain barrier boundaries to interface with satiety pathways in the arcuate nucleus, signaling a down-regulation of food-seeking behaviors and appetite drive pathways.
* **Glucagon Receptor Activation & Browning:** Uniquely activating the Glucagon (GCG) receptor, Retatrutide stimulates energy expenditure directly at the cellular level. It is intensively investigated for its ability to increase metabolic rate via white adipose tissue browning kinetics, liver lipid clearance, and enhanced systemic lipid oxidation ($ \beta\text{-oxidation} $).
* **Synergistic Nutrient Repartitioning:** By firing all three metabolic pathways simultaneously, the compound allows researchers to monitor the concurrent down-regulation of caloric intake alongside a synchronized upregulation of basal calorie clearance.

### Research Applications
In preclinical and in vitro laboratory models, Retatrutide (GLP-3) vials are actively utilized to investigate:
* High-velocity lipid mobilization, visceral adipose tissue browning kinetics, and extreme obesity resistance pathways.
* Pancreatic beta-cell protection, glucose-dependent insulin transcription, and hepatic steatosis clearance metrics.
* Central nervous system satiety pathways, arcuate nucleus neuroplasticity, and behavioral food-seeking motivation curves.
* The comparative baseline efficiency, multi-receptor saturation curves, and energy expenditure spikes of triple GIP/GLP-1/GCG co-agonists.

Our Retatrutide vials undergo strict laboratory stabilization, vacuum-drying, and high-purity purification guidelines to ensure absolute peptide chain integrity, rapid reconstitution kinetics, and dependable experimental reproducibility.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*